Sperm Bank
Sperm Bank
Selection
We are the most demanding
A personal and family medical history is carried out, going back to the grandparents, in order to assess them and rule out hereditary diseases, according to Law 9/2014 and RD 412/1996.
Assessment of the psychological history of the donor and their environment is incorporated following the recommendations of theSociedad Española de Fertilidad (SEF).
As the legislation does not include the exclusion criteria, we proceeded in 2007, with the help of different experts in each subject and in the environment of the Ceifer Training Classroom, to the publication of the book “
REFLECTIONS ON THE EVALUATION OF GAMETE AND EMBRYO DONORS”. This study helps us to carry out the donor selection process.
In CEIFER Biobanco, candidates are only admitted to donors with values much higher than those considered normal by the World Health Organization (WHO).
- Sperm concentration: 80 millones-spz/mL.
- Progressive sperm mobility: 50 %.
- Sperm morphology: 4 %.
- Blood group
- Rh Factor
- Hemogram
- Haemostasis:
- Prothrombin activity
- TTPA
- Biochemistry:
- Glucose
- Creatinine
- Total cholesterol
- HDL cholesterol
- Triglycerides
- Transaminases (GOT,GPT)
|
Disease |
|
| VIH | Ag p24, Ab 1+2 |
| Hepatitis B | HBsAg, HBsAb, HBcAb (IgM, IgG) |
| Hepatitis C | Ab Hepatitis C |
| Syphilis | TPHA-RPR |
| CMV | Ab CMV (IgG, IgM)* |
*If Anti CMV IgM is positive, a study is performed by PCR Ab: Antibodies (antibodies); Ag: antigens (antigens).
CHLAMYIDIA
Chlamydia Trachomatis study is performed by urine PCR.
- TRIAGE + PCR + Serology (anti-IgG and anti-IgM) is performed in the acceptance protocol:
- TRIAJE (-), PCR (-), and antic IgM (-) – Accepted
- TRIAGE (+) or PCR (+), or antic IgM (+) – Not accepted.
- PCR is repeated every 14 days.
- Serology is repeated every 3 months.
Microbiological culture is performed with a double sense:
- Rule out pathogenic microorganisms that can cause pathology in the recipient woman.
- Protect crops grown using IVF of contaminations that endanger the viability of the technique.
Therefore, those donors are discarded and / or samples that do not comply:
- No growth of pathogenic germs.
- Regional flora growth < 1000 CFU / mL.
Our protocol for genetic studies is the most complete of the existing semen banks, both nationally and worldwide.
This allows the removal of candidates to donors who are carriers of pathogenic mutations of the most prevalent genetic diseases, mainly those that, due to their autosomal recessive nature, only manifest in the offspring.
STUDY OF CARRIERS OF MONOGENIC RECESSIVE DISEASES
Genetic studies are carried out that they allow the elimination of donor candidates that are carriers of pathogenic mutations of the most prevalent monogenic recessive diseases in our environment (Mediterranean area of Europe).
| Disease | Gen | Sequencing |
| Fibrosis Quística | CFTR | Ver Tabla 1* |
| Atrofia Muscular Espinal | SMN1 | Full gene |
| Sordera autosómica recesiva Tipo 1A | GJB2 | Full gene |
| Alfa Talasemia | HBA1/HBA2 | Full gene |
| Beta talassemia | HBB | Full gene |
| Fiebre Mediterránea Familiar |
MEFV | Full gene |
| Déficit de fenilalanina hidroxilasa | PAH | Gen completo |
| Enfermedad de Pompe | GAA | Full gene |
| Síndrome de Alport | COL4A4 | Full gene |
| Síndrome de Smith-Lemli-Opitz | DHCR7 | Full gene |
| Enfermedad de Tay Sachs | HEXA | Full gene |
| Déficit de glucosa 6 fosfato deshidrogenasa | G6PD | Full gene |
To reduce the risk of offspring affected by these and other diseases, genetic matching is recommended (more information below inBanco DNA y Matching Genético)
GENETIC MATCHING
Genetic matching enables the donor’s genetic information to be compared with that of the recipient’s male partner, in order to avoid the transmission of genetic diseases. For this, the study of 307 genes related to monogenic recessive diseases is carried out. This analysis is carried out using the most modern massive sequencing techniques (Next Generation Sequencing – NGS).
The 307 genes studied include variants with a particularly high incidence in the Mediterranean area.
The results of our donors are compared with the similar genetic study carried out in the male of the recipient couple, selecting a suitable donor, in such a way that the donor and the male do not share mutations in the same genes.
(The genetic matching protocol does not eliminate the risk in the offspring of suffering or being a carrier of recessive diseases, even if it is one of the diseases studied. Its objective is to significantly reduce risks, < em> depending on this decrease of the disease studied).
GENES STUDIED
| Enfermedad | Gen |
|---|---|
| 17-beta-hydroxysteroid dehydrogenase X deficiency | HSD17B10 |
| 2-methylbutyrylglycinuria | ACADSB |
| 3-Methylcrotonyl-CoA carboxylase 1 deficiency | MCCC1 |
| 3-Methylcrotonyl-CoA carboxylase 2 deficiency | MCCC2 |
| Aarskog-Scott syndrome, Mental retardation, X-linked syndromic 16 | FGD1 |
| Achondrogenesis Ib | SLC26A2 |
| Achromatopsia-3 | CNGB3 |
| Acyl-CoA dehydrogenase, medium chain, deficiency of | ACADM |
| Acyl-CoA dehydrogenase, short-chain, deficiency of | ACADS |
| Acyl-CoA dehydrogenase, short-chain, deficiency of | CYP17A1 |
| Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency | CYP21A2 |
| Adrenoleukodystrophy | ABCD1 |
| Alkaptonuria | HGD |
| Allan-Herndon-Dudley syndrome | SLC16A2 |
| Alpha-methylacetoacetic aciduria | ACAT1 |
| Alpha-thalassemia/mental retardation syndrome | ATRX |
| Alport syndrome, autosomal recessive, | COL4A4 related |
| Anauxetic dysplasia | RMRP |
| Androgen insensitivity | AR |
| Argininemia | ARG1 |
| Argininosuccinic aciduria | ASL |
| Arts Syndrome | PRPS1 |
| Aspartylglucosaminuria | AGA |
| Ataxia with isolated vitamin E deficiency | TTPA |
| Ataxia-telangiectasia | ATM |
| Auditory neuropathy, autosomal recessive, 1 | OTOF |
| Autoimmune polyendocrinopathy syndrome, type I, with or without reversible metaphyseal dysplasia | AIRE |
| Autosomal Recessive Polycystic Kidney Disease (ARPKD) | PKHD1 |
| Bardet-Biedl syndrome 1 | BBS1 |
| Bardet-Biedl syndrome 10 | BBS10 |
| Bardet-Biedl syndrome 14, Joubert syndrome 5, Meckel syndrome 4, Senior-Loken syndrome 6 | CEP290 |
| Bardet-Biedl syndrome 2 | BBS2 |
| Bartter syndrome, type 4a | BSND |
| Biotinidase deficiency | BTD |
| Bjornstad syndrome | BCS1L |
| Canavan disease | ASPA |
| Carbamoylphosphate synthetase I deficiency | CPS1 |
| Carnitine deficiency, systemic primary | SLC22A5 |
| Carnitine-acylcarnitine translocase deficiency | SLC25A20 |
| Cerebral creatine deficiency syndrome 1 | SLC6A8 |
| Cerebrotendinous xanthomatosis | CYP27A1 |
| Ceroid lipofuscinosis, neuronal, 5 | CLN5 |
| Ceroid lipofuscinosis, neuronal, 8 | CLN8 |
| Ceroid lipofuscinosis, neuronal, 10 | CTSD |
| Ceroid lipofuscinosis, neuronal, 3 | CLN3 |
| Ceroid lipofuscinosis, neuronal, 6, 601780 | CLN6 |
| Ceroid lipofuscinosis, neuronal, 7 | MFSD8 |
| Ceroid lipofuscinosis, neuronal, type 1 | PPT1 |
| Ceroid lipofuscinosis, neuronal, type 2 | TPP1 |
| Charcot-Marie-Tooth disease, type 4B1 | MTMR2 |
| Charcot-Marie-Tooth disease, type 4C | SH3TC2 |
| Charcot-Marie-Tooth disease, type 4D | NDRG1 |
| Charcot-Marie-Tooth Neuropathy Type 4A | GDAP1 |
| Cholestasis, benign recurrent intrahepatic, 2 | ABCB11 |
| Citrullinemia | ASS1 |
| Citrullinemia, neonatal-onset type II | SLC25A13 |
| Coffin-Lowry syndrome | RPS6KA3 |
| Combined malonic and methylmalonic acidemia | ACSF3 |
| Cone rod dystrophy 3 | ABCA4 |
| Cone-rod dystrophy, X-linked, 1 | RPGR |
| Congenital disorder of glycosylation, type Ia | PMM2 |
| Corneal endothelial dystrophy and sensorineural deafness (CDPD) | SLC4A11 |
| CPT I (Carnitine Palmitoyltransferase IA) deficiency, hepatic, type IA | CPT1A |
| CPT II (Carnitine Palmitoyltransferase) deficiency, lethal neonatal | CPT2 |
| CRASH/ MASA syndrome | L1CAM |
| Cystathioninuria | CTH |
| Cystic fibrosis, Congenital bilateral absence of vas deferens | CFTR |
| Cystinosis, atypical nephropathic | CTNS |
| Cystinuria | SLC3A1 |
| Cystinuria | SLC7A9 |
| Deafness, autosomal recessive 1A (DFNB1-related) | GJB2 |
| Deafness, autosomal recessive 12 | CDH23 |
| Deafness, autosomal recessive 18A | USH1C |
| Deafness, autosomal recessive 23 | PCDH15 |
| Deafness, autosomal recessive 4, with enlarged vestibular aqueduct | SLC26A4 |
| Deafness, digenic GJB2/GJB3 | GJB3 |
| Dent disease 2 | OCRL |
| Dihydrolipoamide dehydrogenase deficiency | DLD |
| Duchenne muscular dystrophy, Becker muscular dystrophy | DMD |
| Dysprothrombinemia, Prothrombin thrombophilia / Factor II deficiency | F2 |
| Ehlers-Danlos syndrome, type VI | PLOD1 |
| Ellis-van Creveld Syndrome | EVC2 |
| Emphysema due to Alpha1 Anti-Trypsin deficiency | SERPINA1 |
| Epidermolysis bullosa dystrophica, AR | COL7A1 |
| Epidermolysis bullosa, junctional, Herlitz type | LAMB3 |
| Epilepsy, X-linked, with variable learning disabilities and behavior disorders | SYN1 |
| Epileptic encephalopathy, early infantile, 1 | ARX |
| Ethylmalonic encephalopathy | ETHE1 |
| Fabry disease | GLA |
| Factor V Deficiency | F5 |
| Factor XI deficiency, autosomal recessive | F11 |
| Familial Mediterranean fever, autosomal recessive | MEFV |
| Fanconi anemia | FANCA |
| Fanconi anemia, complementation group C | FANCC |
| Folate malabsorption, hereditary | SLC46A1 |
| Fragile X syndrome | FMR1 |
| Friedreich ataxia with retained reflexes | FXN |
| Fructose intolerance | ALDOB |
| Fumarase deficiency | FH |
| G6PD deficiency / Favism | G6PD |
| Galactokinase deficiency with cataracts | GALK1 |
| Galactose epimerase deficiency | GALE |
| Galactosemia | GALT |
| Gaucher disease, perinatal lethal | GBA |
| Glutamate formiminotransferase deficiency | FTCD |
| Glutaric acidemia IIA | ETFA |
| Glutaric acidemia IIB | ETFB |
| Glutaric acidemia IIC | ETFDH |
| Glutaric aciduria, type I | GCDH |
| Glycine encephalopathy | AMT |
| Glycine encephalopathy | GLDC |
| Glycogen storage disease Ia | G6PC |
| Glycogen storage disease Ib | SLC37A4 |
| Glycogen storage disease II / Pompe disease | GAA |
| Glycogen storage disease IIIa | AGL |
| Glycogen storage disease IV | GBE1 |
| GM1-gangliosidosis, types I, II, III | GLB1 |
| Goldmann-Favre syndrome | NR2E3 |
| HARP syndrome | PANK2 |
| Hartnup disorder | SLC6A19 |
| Heimler syndrome, type 2 | PEX6 |
| Hemochromatosis, type 3 | TFR2 |
| Hemochromatosis: Type 2A: HFE2 Related | HFE2 |
| Hemophilia A, factor VIII deficiency, X-linked | F8 |
| Hemophilia B, factor IX deficiency | F9 |
| Herlitz Junctional Epidermolysis Bullosa: LAMC2 Related | LAMC2 |
| Histidinemia | HAL |
| HMG-CoA lyase deficiency | HMGCL |
| Holocarboxylase synthetase deficiency | HLCS |
| Homocystinuria, B6-responsive and nonresponsive types | CBS |
| Homocystinuria-megaloblastic anemia, cbl E type | MTRR |
| Hypercholesterolemia, familial | LDLR |
| Hypercholesterolemia, familial, autosomal recessive | LDLRAP1 |
| Hyperinsulinemic hypoglycemia, familial, type 2 | KCNJ11 |
| Hypermethioninemia due to adenosine kinase deficiency | ADK |
| Hypermethioninemia due to Glycine N-methyltransferase deficiency | GNMT |
| Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase | AHCY |
| Hypermethioninemia, persistent, due to MAT1 deficiency | MAT1A |
| Hyperoxaluria III | HOGA1 |
| Hyperoxaluria, primary, type I | AGXT |
| Hyperoxaluria, primary, type II | GRHPR |
| Hyperphenylalaninemia, BH4-deficient, A | PTS |
| Hyperphenylalaninemia, BH4-deficient, C | QDPR |
| Hyperphenylalaninemia, BH4-deficient, D | PCBD1 |
| Hyperprolinemia, type II | ALDH4A1 |
| Hypogonadotropic hypogonadism 7 without anosmia | GNRHR |
| Hypothryoidism, congenital, nongoitrous 4 | TSHB |
| Hypothyroidism, congenital, nongoitrous 1 | TSHR |
| Ichthyosis, congenital, autosomal recessive 1 | TGM1 |
| Immunodeficiency, X-linked, with hyper-IgM | CD40LG |
| Isovaleric acidemia | IVD |
| Joubert syndrome 2 | TMEM216 |
| Joubert syndrome 4 | NPHP1 |
| Joubert syndrome 8 | ARL13B |
| Joubert syndrome-3 | AHI1 |
| Krabbe disease | GALC |
| LCHAD deficiency | HADHA |
| Leber congenital amaurosis 13 | RDH12 |
| Leber congenital amaurosis 2 | RPE65 |
| Leber congenital amaurosis 8 | CRB1 |
| Leber congenital amaurosis-1 | GUCY2D |
| Leber congenital amaurosis-4 | AIPL1 |
| Leigh syndrome, French-Canadian type | LRPPRC |
| Leigh syndrome, due to COX deficiency | SURF1 |
| limb-girdle muscular dystrophy type 2B | DYSF |
| Lipoid adrenal hyperplasia | STAR |
| Lissencephaly, X-linked | DCX |
| Macular corneal dystrophy | CHST6 |
| Malonyl-CoA decarboxylase deficiency, 248360 | MLYCD |
| Mannosidosis, alpha-, types I and II | MAN2B1 |
| Maple syrup urine disease, type II | DBT |
| Maple syrup urine disease, type Ia | BCKDHA |
| Maple syrup urine disease, type Ib | BCKDHB |
| McArdle disease / Glycogen Storage Disease: Type V | PYGM |
| Meckel syndrome 1 | MKS1 |
| Mental retardation and microcephaly with pontine and cerebellar hypoplasia | CASK |
| Mental retardation syndrome, X-linked, Siderius type | PHF8 |
| Mental retardation, X-linked | OPHN1 |
| Mental retardation, X-linked 1/78 | IQSEC2 |
| Mental retardation, X-linked 12/35 | THOC2 |
| Mental retardation, X-linked 21/34 | IL1RAPL1 |
| Mental retardation, X-linked 30/47 | PAK3 |
| Mental retardation, X-linked 41 | GDI1 |
| Mental retardation, X-linked 58 | TSPAN7 |
| Mental retardation, X-linked 63 | ACSL4 |
| Mental retardation, X-linked 9 | FTSJ1 |
| Mental retardation, X-linked 90 | DLG3 |
| Mental retardation, X-linked 94 | GRIA3 |
| Mental retardation, X-linked 97 | ZNF711 |
| Mental retardation, X-linked 99 | USP9X |
| Mental retardation, X-linked syndromic 5 | AP1S2 |
| Mental retardation, X-linked syndromic, Raymond type | ZDHHC9 |
| Mental retardation, X-linked syndromic, Turner type | HUWE1 |
| Mental retardation, X-linked, Asperger syndrome susceptibility, X-linked | NLGN4X |
| Mental retardation, X-linked, FRAXE type | AFF2 |
| Mental retardation, X-linked, syndromic 13 | MECP2 |
| Mental retardation, X-linked, syndromic 14 | UPF3B |
| Mental retardation, X-linked, syndromic 15 | CUL4B |
| Mental retardation, X-linked, syndromic, Claes-Jensen type | KDM5C |
| Metachromatic leukodystrophy | ARSA |
| Methylmalonic aciduria and homocystinuria, cblC type | MMACHC |
| Methylmalonic aciduria and homocystinuria, cblD type | MMADHC |
| Methylmalonic aciduria and homocystinuria, cblF type | LMBRD1 |
| Methylmalonic aciduria, vitamin B12-responsive, cbIB type | MMAB |
| Methylmalonic aciduria, vitamin B12-responsive, cblA type | MMAA |
| Methylmalonic aciduria, mut(0) type | MUT |
| Methylmalonic and propionic acidemia and homocystinuria, cbIJ type | ABCD4 |
| Methylmalonyl-CoA epimerase deficiency | MCEE |
| Mevalonic aciduria | MVK |
| Microphthalmia, isolated 3 | RAX |
| MTHFR Deficiency | MTHFR |
| Mucolipidosis III alpha/beta, and type II | GNPTAB |
| Mucolipidosis IV | MCOLN1 |
| Mucopolysaccharidosis Ih / Hurler Syndrome | IDUA |
| Mucopolysaccharidosis II / Hunter Syndrome: X-linked | IDS |
| Mucopolysaccharidosis IVA | GALNS |
| Mucopolysaccharidosis type IIIA (Sanfilippo A) | SGSH |
| Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 | NAGLU |
| Mucopolysaccharidosis type IIIC (Sanfilippo C) | HGSNAT |
| Mucopolysaccharidosis type IIID | GNS |
| Mucopolysaccharidosis type VI (Maroteaux-Lamy) | ARSB |
| Muscular dystrophy, limb-girdle, 2A | CAPN3 |
| Muscular dystrophy, limb-girdle, type 2D | SGCA |
| Muscular dystrophy, limb-girdle, type 2E | SGCB |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) | POMGNT1 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1 | POMT1 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2 | POMT2 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5 | FKRP |
| Myotonia congenita, dominant | CLCN1 |
| Nemaline myopathy 2, autosomal recessive | NEB |
| Nephrotic syndrome, type 1 (Finnish Type) | NPHS1 |
| Neutropenia, severe congenital 3, autosomal recessive | HAX1 |
| Niemann-Pick disease, type A | SMPD1 |
| Niemann-Pick Disease, Type C2 | NPC2 |
| Niemann-Pick Disease: Type C1 | NPC1 |
| Nijmegen breakage syndrome | NBN |
| Norrie disease | NDP |
| Nystagmus 6, congenital, X-linked | GPR143 |
| Ornithine transcarbamylase deficiency | OTC |
| Osteogenesis imperfecta, type VIII | P3H1 |
| Pelizaeus-Merzbacher disease, 312080 | PLP1 |
| Peroxisomal acyl-CoA oxidase deficiency | ACOX1 |
| Peroxisome biogenesis disorde 6A, Zellweger syndrome | PEX10 |
| Peroxisome biogenesis disorder 1A, Zellweger syndrome-1 | PEX1 |
| Phenylketonuria | PAH |
| Phosphoglycerate kinase 1 deficiency | PGK1 |
| Pituitary hormone deficiency, combined, 2 | PROP1 |
| Primary ciliary dyskinesia | DNAH5 |
| Propionic acidemia | PCCA |
| Propionic acidemia | PCCB |
| Pyruvate carboxylase deficiency | PC |
| Pyruvate dehydrogenase E1-beta deficiency | PDHB |
| Renpenning syndrome | PQBP1 |
| Retinitis pigmentosa 2 | RP2 |
| Retinitis pigmentosa 25 | EYS |
| Retinitis pigmentosa 26 | CERKL |
| Retinitis pigmentosa 39 | USH2A |
| Retinitis pigmentosa 43 | PDE6A |
| Retinitis pigmentosa 45 | CNGB1 |
| Retinitis pigmentosa 46 | IDH3B |
| Retinitis pigmentosa 49 | CNGA1 |
| Retinitis pigmentosa 59 | DHDDS |
| Retinoschisis: X-linked | RS1 |
| Rhizomelic chondrodysplasia punctata, type 1; Peroxisome biogenesis disorder | PEX7 |
| Rhizomelic chondrodysplasia punctata, type 3 | AGPS |
| Sandhoff disease, infantile, juvenile, and adult forms | HEXB |
| SCID, autosomal recessive, T-negative/B-positive type | JAK3 |
| Segawa syndrome, recessive (tyrosine hydroxylase deficiency) | TH |
| Severe combined immunodeficiency due to ADA deficiency | ADA |
| Severe combined immunodeficiency, X-linked | IL2RG |
| Smith-Lemli-Opitz syndrome | DHCR7 |
| Spastic ataxia, Charlevoix-Saguenay type (ARSACS) | SACS |
| Spastic paraplegia 11, autosomal recessive | SPG11 |
| Spastic paraplegia 7, autosomal recessive | SPG7 |
| Spinalmuscle atrophy (several types) | SMN1 |
| Tay-Sachs disease, GM2-gangliosidisus, several forms | HEXA |
| Thalassemia, alpha- | HBA1 |
| Thalassemia, alpha- | HBA2 |
| Thalassemias, beta- (Sickle Cell Anemia) | HBB |
| Thrombocytopenia, congenital amegakaryocytic | MPL |
| Thryoid dyshormonogenesis 6 | DUOX2 |
| Thyroid dyshormonogenesis 1 | SLC5A5 |
| Thyroid dyshormonogenesis 2A | TPO |
| Thyroid dyshormonogenesis 3 | TG |
| Thyroid dyshormonogenesis 4 | IYD |
| Thyroid dyshormonogenesis 5 | DUOXA2 |
| Thyroid hormone resistance | THRB |
| Treacher Collins syndrome 3 | POLR1C |
| Trifunctional protein deficiency | HADHB |
| Tyrosinemia, type I | FAH |
| Tyrosinemia, type II | TAT |
| Usher syndrome, type 1B; Deafness, autosomal dominant 11 | MYO7A |
| Usher syndrome, type 1G | USH1G |
| Usher syndrome, type 2D / Deafness, autosomal recessive 31 | WHRN |
| Usher syndrome, type 3A | CLRN1 |
| Ventricular tachycardia, catecholaminergic polymorphic, 2 | CASQ2 |
| Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 | TRDN |
| VLCAD deficiency | ACADVL |
| Walker-Warburg syndrome (congenital with brain and eye anomalies) | FKTN |
| Wilson disease | ATP7B |
| Wolman disease (lysosomal acid lipase deficiency) | LIPA |
| X-linked mental retardation (XLMR) associated with macrocephaly | BRWD3 |
| X-linked mixed deafness with perilymphatic gusher | POU3F4 |
BANK OF DNA
Since 2005 CEIFER Biobanco has had a donor DNA bank. In this way, in case of the appearance of genetic disease in the offspring, we can carry out the pertinent studies. CEIFER Biobanco thus has a global vision and the most advanced technology to:
- Study genetic diseases by cases of live births affected in the offspring.
- Incorporate the study of new genetic diseases in donor screening.
Our donors are subjected to a rigorous selection protocol, which is in continuous renewal and study, incorporating new tests, improving existing ones and always with the aim of offering the maximum possibilities of the gestation of a HEALTHY CHILD.
The age is between 18-35 years old and the most common profile is that of a university student and Spanish nationality.
Selection
We are the most demanding
Our donors are subjected to a rigorous selection protocol, which is in continuous renewal and study, incorporating new tests, improving existing ones and always with the aim of offering the maximum possibilities of the gestation of a HEALTHY CHILD.
The age is between 18-35 years old and the most common profile is that of a university student and Spanish nationality.
A personal and family medical history is carried out, going back to the grandparents, in order to assess them and rule out hereditary diseases, according to Law 9/2014 and RD 412/1996.
Assessment of the psychological history of the donor and their environment is incorporated following the recommendations of theSociedad Española de Fertilidad (SEF).
As the legislation does not include the exclusion criteria, we proceeded in 2007, with the help of different experts in each subject and in the environment of the Ceifer Training Classroom, to the publication of the book “
REFLECTIONS ON THE EVALUATION OF GAMETE AND EMBRYO DONORS”. This study helps us to carry out the donor selection process.
In CEIFER Biobanco, candidates are only admitted to donors with values much higher than those considered normal by the World Health Organization (WHO).
- Sperm concentration: 80 millones-spz/mL.
- Progressive sperm mobility: 50 %.
- Sperm morphology: 4 %.
- Blood group
- Rh Factor
- Hemogram
- Haemostasis:
- Prothrombin activity
- TTPA
- Biochemistry:
- Glucose
- Creatinine
- Total cholesterol
- HDL cholesterol
- Triglycerides
- Transaminases (GOT,GPT)
|
Disease |
|
| VIH | Ag p24, Ab 1+2 |
| Hepatitis B | HBsAg, HBsAb, HBcAb (IgM, IgG) |
| Hepatitis C | Ab Hepatitis C |
| Syphilis | TPHA-RPR |
| CMV | Ab CMV (IgG, IgM)* |
*If Anti CMV IgM is positive, a study is performed by PCR Ab: Antibodies (antibodies); Ag: antigens (antigens).
CHLAMYIDIA
Chlamydia Trachomatis study is performed by urine PCR.
- TRIAGE + PCR + Serology (anti-IgG and anti-IgM) is performed in the acceptance protocol:
- TRIAJE (-), PCR (-), and antic IgM (-) – Accepted
- TRIAGE (+) or PCR (+), or antic IgM (+) – Not accepted.
- PCR is repeated every 14 days.
- Serology is repeated every 3 months.
Microbiological culture is performed with a double sense:
- Rule out pathogenic microorganisms that can cause pathology in the recipient woman.
- Protect crops grown using IVF of contaminations that endanger the viability of the technique.
Therefore, those donors are discarded and / or samples that do not comply:
- No growth of pathogenic germs.
- Regional flora growth < 1000 CFU / mL.
Our protocol for genetic studies is the most complete of the existing semen banks, both nationally and worldwide.
This allows the removal of candidates to donors who are carriers of pathogenic mutations of the most prevalent genetic diseases, mainly those that, due to their autosomal recessive nature, only manifest in the offspring.
STUDY OF CARRIERS OF MONOGENIC RECESSIVE DISEASES
Genetic studies are carried out that they allow the elimination of donor candidates that are carriers of pathogenic mutations of the most prevalent monogenic recessive diseases in our environment (Mediterranean area of Europe).
| Disease | Gen | Sequencing |
| Fibrosis Quística | CFTR | Ver Tabla 1* |
| Atrofia Muscular Espinal | SMN1 | Full gene |
| Sordera autosómica recesiva Tipo 1A | GJB2 | Full gene |
| Alfa Talasemia | HBA1/HBA2 | Full gene |
| Beta talassemia | HBB | Full gene |
| Fiebre Mediterránea Familiar |
MEFV | Full gene |
| Déficit de fenilalanina hidroxilasa | PAH | Gen completo |
| Enfermedad de Pompe | GAA | Full gene |
| Síndrome de Alport | COL4A4 | Full gene |
| Síndrome de Smith-Lemli-Opitz | DHCR7 | Full gene |
| Enfermedad de Tay Sachs | HEXA | Full gene |
| Déficit de glucosa 6 fosfato deshidrogenasa | G6PD | Full gene |
To reduce the risk of offspring affected by these and other diseases, genetic matching is recommended (more information below inBanco DNA y Matching Genético)
GENETIC MATCHING
Genetic matching enables the donor’s genetic information to be compared with that of the recipient’s male partner, in order to avoid the transmission of genetic diseases. For this, the study of 307 genes related to monogenic recessive diseases is carried out. This analysis is carried out using the most modern massive sequencing techniques (Next Generation Sequencing – NGS).
The 307 genes studied include variants with a particularly high incidence in the Mediterranean area.
The results of our donors are compared with the similar genetic study carried out in the male of the recipient couple, selecting a suitable donor, in such a way that the donor and the male do not share mutations in the same genes.
(The genetic matching protocol does not eliminate the risk in the offspring of suffering or being a carrier of recessive diseases, even if it is one of the diseases studied. Its objective is to significantly reduce risks, < em> depending on this decrease of the disease studied).
GENES STUDIED
| Enfermedad | Gen |
|---|---|
| 17-beta-hydroxysteroid dehydrogenase X deficiency | HSD17B10 |
| 2-methylbutyrylglycinuria | ACADSB |
| 3-Methylcrotonyl-CoA carboxylase 1 deficiency | MCCC1 |
| 3-Methylcrotonyl-CoA carboxylase 2 deficiency | MCCC2 |
| Aarskog-Scott syndrome, Mental retardation, X-linked syndromic 16 | FGD1 |
| Achondrogenesis Ib | SLC26A2 |
| Achromatopsia-3 | CNGB3 |
| Acyl-CoA dehydrogenase, medium chain, deficiency of | ACADM |
| Acyl-CoA dehydrogenase, short-chain, deficiency of | ACADS |
| Acyl-CoA dehydrogenase, short-chain, deficiency of | CYP17A1 |
| Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency | CYP21A2 |
| Adrenoleukodystrophy | ABCD1 |
| Alkaptonuria | HGD |
| Allan-Herndon-Dudley syndrome | SLC16A2 |
| Alpha-methylacetoacetic aciduria | ACAT1 |
| Alpha-thalassemia/mental retardation syndrome | ATRX |
| Alport syndrome, autosomal recessive, | COL4A4 related |
| Anauxetic dysplasia | RMRP |
| Androgen insensitivity | AR |
| Argininemia | ARG1 |
| Argininosuccinic aciduria | ASL |
| Arts Syndrome | PRPS1 |
| Aspartylglucosaminuria | AGA |
| Ataxia with isolated vitamin E deficiency | TTPA |
| Ataxia-telangiectasia | ATM |
| Auditory neuropathy, autosomal recessive, 1 | OTOF |
| Autoimmune polyendocrinopathy syndrome, type I, with or without reversible metaphyseal dysplasia | AIRE |
| Autosomal Recessive Polycystic Kidney Disease (ARPKD) | PKHD1 |
| Bardet-Biedl syndrome 1 | BBS1 |
| Bardet-Biedl syndrome 10 | BBS10 |
| Bardet-Biedl syndrome 14, Joubert syndrome 5, Meckel syndrome 4, Senior-Loken syndrome 6 | CEP290 |
| Bardet-Biedl syndrome 2 | BBS2 |
| Bartter syndrome, type 4a | BSND |
| Biotinidase deficiency | BTD |
| Bjornstad syndrome | BCS1L |
| Canavan disease | ASPA |
| Carbamoylphosphate synthetase I deficiency | CPS1 |
| Carnitine deficiency, systemic primary | SLC22A5 |
| Carnitine-acylcarnitine translocase deficiency | SLC25A20 |
| Cerebral creatine deficiency syndrome 1 | SLC6A8 |
| Cerebrotendinous xanthomatosis | CYP27A1 |
| Ceroid lipofuscinosis, neuronal, 5 | CLN5 |
| Ceroid lipofuscinosis, neuronal, 8 | CLN8 |
| Ceroid lipofuscinosis, neuronal, 10 | CTSD |
| Ceroid lipofuscinosis, neuronal, 3 | CLN3 |
| Ceroid lipofuscinosis, neuronal, 6, 601780 | CLN6 |
| Ceroid lipofuscinosis, neuronal, 7 | MFSD8 |
| Ceroid lipofuscinosis, neuronal, type 1 | PPT1 |
| Ceroid lipofuscinosis, neuronal, type 2 | TPP1 |
| Charcot-Marie-Tooth disease, type 4B1 | MTMR2 |
| Charcot-Marie-Tooth disease, type 4C | SH3TC2 |
| Charcot-Marie-Tooth disease, type 4D | NDRG1 |
| Charcot-Marie-Tooth Neuropathy Type 4A | GDAP1 |
| Cholestasis, benign recurrent intrahepatic, 2 | ABCB11 |
| Citrullinemia | ASS1 |
| Citrullinemia, neonatal-onset type II | SLC25A13 |
| Coffin-Lowry syndrome | RPS6KA3 |
| Combined malonic and methylmalonic acidemia | ACSF3 |
| Cone rod dystrophy 3 | ABCA4 |
| Cone-rod dystrophy, X-linked, 1 | RPGR |
| Congenital disorder of glycosylation, type Ia | PMM2 |
| Corneal endothelial dystrophy and sensorineural deafness (CDPD) | SLC4A11 |
| CPT I (Carnitine Palmitoyltransferase IA) deficiency, hepatic, type IA | CPT1A |
| CPT II (Carnitine Palmitoyltransferase) deficiency, lethal neonatal | CPT2 |
| CRASH/ MASA syndrome | L1CAM |
| Cystathioninuria | CTH |
| Cystic fibrosis, Congenital bilateral absence of vas deferens | CFTR |
| Cystinosis, atypical nephropathic | CTNS |
| Cystinuria | SLC3A1 |
| Cystinuria | SLC7A9 |
| Deafness, autosomal recessive 1A (DFNB1-related) | GJB2 |
| Deafness, autosomal recessive 12 | CDH23 |
| Deafness, autosomal recessive 18A | USH1C |
| Deafness, autosomal recessive 23 | PCDH15 |
| Deafness, autosomal recessive 4, with enlarged vestibular aqueduct | SLC26A4 |
| Deafness, digenic GJB2/GJB3 | GJB3 |
| Dent disease 2 | OCRL |
| Dihydrolipoamide dehydrogenase deficiency | DLD |
| Duchenne muscular dystrophy, Becker muscular dystrophy | DMD |
| Dysprothrombinemia, Prothrombin thrombophilia / Factor II deficiency | F2 |
| Ehlers-Danlos syndrome, type VI | PLOD1 |
| Ellis-van Creveld Syndrome | EVC2 |
| Emphysema due to Alpha1 Anti-Trypsin deficiency | SERPINA1 |
| Epidermolysis bullosa dystrophica, AR | COL7A1 |
| Epidermolysis bullosa, junctional, Herlitz type | LAMB3 |
| Epilepsy, X-linked, with variable learning disabilities and behavior disorders | SYN1 |
| Epileptic encephalopathy, early infantile, 1 | ARX |
| Ethylmalonic encephalopathy | ETHE1 |
| Fabry disease | GLA |
| Factor V Deficiency | F5 |
| Factor XI deficiency, autosomal recessive | F11 |
| Familial Mediterranean fever, autosomal recessive | MEFV |
| Fanconi anemia | FANCA |
| Fanconi anemia, complementation group C | FANCC |
| Folate malabsorption, hereditary | SLC46A1 |
| Fragile X syndrome | FMR1 |
| Friedreich ataxia with retained reflexes | FXN |
| Fructose intolerance | ALDOB |
| Fumarase deficiency | FH |
| G6PD deficiency / Favism | G6PD |
| Galactokinase deficiency with cataracts | GALK1 |
| Galactose epimerase deficiency | GALE |
| Galactosemia | GALT |
| Gaucher disease, perinatal lethal | GBA |
| Glutamate formiminotransferase deficiency | FTCD |
| Glutaric acidemia IIA | ETFA |
| Glutaric acidemia IIB | ETFB |
| Glutaric acidemia IIC | ETFDH |
| Glutaric aciduria, type I | GCDH |
| Glycine encephalopathy | AMT |
| Glycine encephalopathy | GLDC |
| Glycogen storage disease Ia | G6PC |
| Glycogen storage disease Ib | SLC37A4 |
| Glycogen storage disease II / Pompe disease | GAA |
| Glycogen storage disease IIIa | AGL |
| Glycogen storage disease IV | GBE1 |
| GM1-gangliosidosis, types I, II, III | GLB1 |
| Goldmann-Favre syndrome | NR2E3 |
| HARP syndrome | PANK2 |
| Hartnup disorder | SLC6A19 |
| Heimler syndrome, type 2 | PEX6 |
| Hemochromatosis, type 3 | TFR2 |
| Hemochromatosis: Type 2A: HFE2 Related | HFE2 |
| Hemophilia A, factor VIII deficiency, X-linked | F8 |
| Hemophilia B, factor IX deficiency | F9 |
| Herlitz Junctional Epidermolysis Bullosa: LAMC2 Related | LAMC2 |
| Histidinemia | HAL |
| HMG-CoA lyase deficiency | HMGCL |
| Holocarboxylase synthetase deficiency | HLCS |
| Homocystinuria, B6-responsive and nonresponsive types | CBS |
| Homocystinuria-megaloblastic anemia, cbl E type | MTRR |
| Hypercholesterolemia, familial | LDLR |
| Hypercholesterolemia, familial, autosomal recessive | LDLRAP1 |
| Hyperinsulinemic hypoglycemia, familial, type 2 | KCNJ11 |
| Hypermethioninemia due to adenosine kinase deficiency | ADK |
| Hypermethioninemia due to Glycine N-methyltransferase deficiency | GNMT |
| Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase | AHCY |
| Hypermethioninemia, persistent, due to MAT1 deficiency | MAT1A |
| Hyperoxaluria III | HOGA1 |
| Hyperoxaluria, primary, type I | AGXT |
| Hyperoxaluria, primary, type II | GRHPR |
| Hyperphenylalaninemia, BH4-deficient, A | PTS |
| Hyperphenylalaninemia, BH4-deficient, C | QDPR |
| Hyperphenylalaninemia, BH4-deficient, D | PCBD1 |
| Hyperprolinemia, type II | ALDH4A1 |
| Hypogonadotropic hypogonadism 7 without anosmia | GNRHR |
| Hypothryoidism, congenital, nongoitrous 4 | TSHB |
| Hypothyroidism, congenital, nongoitrous 1 | TSHR |
| Ichthyosis, congenital, autosomal recessive 1 | TGM1 |
| Immunodeficiency, X-linked, with hyper-IgM | CD40LG |
| Isovaleric acidemia | IVD |
| Joubert syndrome 2 | TMEM216 |
| Joubert syndrome 4 | NPHP1 |
| Joubert syndrome 8 | ARL13B |
| Joubert syndrome-3 | AHI1 |
| Krabbe disease | GALC |
| LCHAD deficiency | HADHA |
| Leber congenital amaurosis 13 | RDH12 |
| Leber congenital amaurosis 2 | RPE65 |
| Leber congenital amaurosis 8 | CRB1 |
| Leber congenital amaurosis-1 | GUCY2D |
| Leber congenital amaurosis-4 | AIPL1 |
| Leigh syndrome, French-Canadian type | LRPPRC |
| Leigh syndrome, due to COX deficiency | SURF1 |
| limb-girdle muscular dystrophy type 2B | DYSF |
| Lipoid adrenal hyperplasia | STAR |
| Lissencephaly, X-linked | DCX |
| Macular corneal dystrophy | CHST6 |
| Malonyl-CoA decarboxylase deficiency, 248360 | MLYCD |
| Mannosidosis, alpha-, types I and II | MAN2B1 |
| Maple syrup urine disease, type II | DBT |
| Maple syrup urine disease, type Ia | BCKDHA |
| Maple syrup urine disease, type Ib | BCKDHB |
| McArdle disease / Glycogen Storage Disease: Type V | PYGM |
| Meckel syndrome 1 | MKS1 |
| Mental retardation and microcephaly with pontine and cerebellar hypoplasia | CASK |
| Mental retardation syndrome, X-linked, Siderius type | PHF8 |
| Mental retardation, X-linked | OPHN1 |
| Mental retardation, X-linked 1/78 | IQSEC2 |
| Mental retardation, X-linked 12/35 | THOC2 |
| Mental retardation, X-linked 21/34 | IL1RAPL1 |
| Mental retardation, X-linked 30/47 | PAK3 |
| Mental retardation, X-linked 41 | GDI1 |
| Mental retardation, X-linked 58 | TSPAN7 |
| Mental retardation, X-linked 63 | ACSL4 |
| Mental retardation, X-linked 9 | FTSJ1 |
| Mental retardation, X-linked 90 | DLG3 |
| Mental retardation, X-linked 94 | GRIA3 |
| Mental retardation, X-linked 97 | ZNF711 |
| Mental retardation, X-linked 99 | USP9X |
| Mental retardation, X-linked syndromic 5 | AP1S2 |
| Mental retardation, X-linked syndromic, Raymond type | ZDHHC9 |
| Mental retardation, X-linked syndromic, Turner type | HUWE1 |
| Mental retardation, X-linked, Asperger syndrome susceptibility, X-linked | NLGN4X |
| Mental retardation, X-linked, FRAXE type | AFF2 |
| Mental retardation, X-linked, syndromic 13 | MECP2 |
| Mental retardation, X-linked, syndromic 14 | UPF3B |
| Mental retardation, X-linked, syndromic 15 | CUL4B |
| Mental retardation, X-linked, syndromic, Claes-Jensen type | KDM5C |
| Metachromatic leukodystrophy | ARSA |
| Methylmalonic aciduria and homocystinuria, cblC type | MMACHC |
| Methylmalonic aciduria and homocystinuria, cblD type | MMADHC |
| Methylmalonic aciduria and homocystinuria, cblF type | LMBRD1 |
| Methylmalonic aciduria, vitamin B12-responsive, cbIB type | MMAB |
| Methylmalonic aciduria, vitamin B12-responsive, cblA type | MMAA |
| Methylmalonic aciduria, mut(0) type | MUT |
| Methylmalonic and propionic acidemia and homocystinuria, cbIJ type | ABCD4 |
| Methylmalonyl-CoA epimerase deficiency | MCEE |
| Mevalonic aciduria | MVK |
| Microphthalmia, isolated 3 | RAX |
| MTHFR Deficiency | MTHFR |
| Mucolipidosis III alpha/beta, and type II | GNPTAB |
| Mucolipidosis IV | MCOLN1 |
| Mucopolysaccharidosis Ih / Hurler Syndrome | IDUA |
| Mucopolysaccharidosis II / Hunter Syndrome: X-linked | IDS |
| Mucopolysaccharidosis IVA | GALNS |
| Mucopolysaccharidosis type IIIA (Sanfilippo A) | SGSH |
| Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 | NAGLU |
| Mucopolysaccharidosis type IIIC (Sanfilippo C) | HGSNAT |
| Mucopolysaccharidosis type IIID | GNS |
| Mucopolysaccharidosis type VI (Maroteaux-Lamy) | ARSB |
| Muscular dystrophy, limb-girdle, 2A | CAPN3 |
| Muscular dystrophy, limb-girdle, type 2D | SGCA |
| Muscular dystrophy, limb-girdle, type 2E | SGCB |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) | POMGNT1 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1 | POMT1 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2 | POMT2 |
| Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5 | FKRP |
| Myotonia congenita, dominant | CLCN1 |
| Nemaline myopathy 2, autosomal recessive | NEB |
| Nephrotic syndrome, type 1 (Finnish Type) | NPHS1 |
| Neutropenia, severe congenital 3, autosomal recessive | HAX1 |
| Niemann-Pick disease, type A | SMPD1 |
| Niemann-Pick Disease, Type C2 | NPC2 |
| Niemann-Pick Disease: Type C1 | NPC1 |
| Nijmegen breakage syndrome | NBN |
| Norrie disease | NDP |
| Nystagmus 6, congenital, X-linked | GPR143 |
| Ornithine transcarbamylase deficiency | OTC |
| Osteogenesis imperfecta, type VIII | P3H1 |
| Pelizaeus-Merzbacher disease, 312080 | PLP1 |
| Peroxisomal acyl-CoA oxidase deficiency | ACOX1 |
| Peroxisome biogenesis disorde 6A, Zellweger syndrome | PEX10 |
| Peroxisome biogenesis disorder 1A, Zellweger syndrome-1 | PEX1 |
| Phenylketonuria | PAH |
| Phosphoglycerate kinase 1 deficiency | PGK1 |
| Pituitary hormone deficiency, combined, 2 | PROP1 |
| Primary ciliary dyskinesia | DNAH5 |
| Propionic acidemia | PCCA |
| Propionic acidemia | PCCB |
| Pyruvate carboxylase deficiency | PC |
| Pyruvate dehydrogenase E1-beta deficiency | PDHB |
| Renpenning syndrome | PQBP1 |
| Retinitis pigmentosa 2 | RP2 |
| Retinitis pigmentosa 25 | EYS |
| Retinitis pigmentosa 26 | CERKL |
| Retinitis pigmentosa 39 | USH2A |
| Retinitis pigmentosa 43 | PDE6A |
| Retinitis pigmentosa 45 | CNGB1 |
| Retinitis pigmentosa 46 | IDH3B |
| Retinitis pigmentosa 49 | CNGA1 |
| Retinitis pigmentosa 59 | DHDDS |
| Retinoschisis: X-linked | RS1 |
| Rhizomelic chondrodysplasia punctata, type 1; Peroxisome biogenesis disorder | PEX7 |
| Rhizomelic chondrodysplasia punctata, type 3 | AGPS |
| Sandhoff disease, infantile, juvenile, and adult forms | HEXB |
| SCID, autosomal recessive, T-negative/B-positive type | JAK3 |
| Segawa syndrome, recessive (tyrosine hydroxylase deficiency) | TH |
| Severe combined immunodeficiency due to ADA deficiency | ADA |
| Severe combined immunodeficiency, X-linked | IL2RG |
| Smith-Lemli-Opitz syndrome | DHCR7 |
| Spastic ataxia, Charlevoix-Saguenay type (ARSACS) | SACS |
| Spastic paraplegia 11, autosomal recessive | SPG11 |
| Spastic paraplegia 7, autosomal recessive | SPG7 |
| Spinalmuscle atrophy (several types) | SMN1 |
| Tay-Sachs disease, GM2-gangliosidisus, several forms | HEXA |
| Thalassemia, alpha- | HBA1 |
| Thalassemia, alpha- | HBA2 |
| Thalassemias, beta- (Sickle Cell Anemia) | HBB |
| Thrombocytopenia, congenital amegakaryocytic | MPL |
| Thryoid dyshormonogenesis 6 | DUOX2 |
| Thyroid dyshormonogenesis 1 | SLC5A5 |
| Thyroid dyshormonogenesis 2A | TPO |
| Thyroid dyshormonogenesis 3 | TG |
| Thyroid dyshormonogenesis 4 | IYD |
| Thyroid dyshormonogenesis 5 | DUOXA2 |
| Thyroid hormone resistance | THRB |
| Treacher Collins syndrome 3 | POLR1C |
| Trifunctional protein deficiency | HADHB |
| Tyrosinemia, type I | FAH |
| Tyrosinemia, type II | TAT |
| Usher syndrome, type 1B; Deafness, autosomal dominant 11 | MYO7A |
| Usher syndrome, type 1G | USH1G |
| Usher syndrome, type 2D / Deafness, autosomal recessive 31 | WHRN |
| Usher syndrome, type 3A | CLRN1 |
| Ventricular tachycardia, catecholaminergic polymorphic, 2 | CASQ2 |
| Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 | TRDN |
| VLCAD deficiency | ACADVL |
| Walker-Warburg syndrome (congenital with brain and eye anomalies) | FKTN |
| Wilson disease | ATP7B |
| Wolman disease (lysosomal acid lipase deficiency) | LIPA |
| X-linked mental retardation (XLMR) associated with macrocephaly | BRWD3 |
| X-linked mixed deafness with perilymphatic gusher | POU3F4 |
BANK OF DNA
Since 2005 CEIFER Biobanco has had a donor DNA bank. In this way, in case of the appearance of genetic disease in the offspring, we can carry out the pertinent studies. CEIFER Biobanco thus has a global vision and the most advanced technology to:
- Study genetic diseases by cases of live births affected in the offspring.
- Incorporate the study of new genetic diseases in donor screening.
We have automated our processes
freezing and storage
Safety and Quality
We have automated our processes
freezing and storage
Safety and Quality
Processes
We only use media
with CE marking
We use freezing media certified by the competent authority (CE marking) for use in humans.
- This leads us to comply with the recommendations more demanding dictated by international organizations for human cell and tissue banks (European Directive 2004/23 / EC and Law 9/2014).
- It ensures the traceability of this process , allowing us, in the event of an incident, to know the manufacturing batch and obtain information that identifies the problem.
- Guarantees the sterility of our process of freezing.
In our freezing process we use straws heat sealable high biological safety (CBS brand).
- The construction material of these straws (resin type) gives them great flexibility, making them practically unbreakable and eliminating the great problem of traditional straws.
- The impossibility of breaking and the fact The fact that the straws are sealed by heat sealing ensures that semen never comes into contact with liquid nitrogen and reduces the risk of contamination between samples to almost zero.
The straws are identified with a CODE UNIQUE that incorporates serial code and donor code. This allows us the traceability of each straw.
- Printing of donor code, making it impossible in this way the confusion between straws from different donors.
- Impossibility of external code manipulation, as it cannot be deleted without destroying the tag.
- Easy identification by the Center of Receiver playback.
We use a filling and heat sealing equipment automatic (CBS).
- It allows not to manipulate the sample, eliminating the possibility of contamination and errors in this part of the process.
- Homogeneity of the filling of straws. < / span>
- Closing by automatic heat sealing, preventing the possibility of contamination between samples due to breakage of the closure system, a problem inherent in sealing traditional straws and cryotubes.
Our freezing process is done with Computerized bio-freezers, specific for semen (Cryologic CL-8800i).
- Optimization and homogeneity of results, by be able to reproduce the intensity and freezing time.
- Decreased possibility of external contamination, typical of open freezing processes.
- Traceability of process temperature freezing, allowing to save the curve of all our freezes.
